Experts flag eye inflammation reports tied to Apellis' geographic atrophy med Syfovre
Fierce Pharma
JULY 17, 2023
Apellis Pharmaceuticals' Syfovre, after achieving the first FDA approval for advanced eye disease geographic atrophy, has been associated with rare but severe side effects, according to the America | The American Society of Retinal Specialists sent out a note to doctors on Saturday warning of eye inflammation cases in patients who took Syfovre, (..)
Let's personalize your content